Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial ... - Business Wire (press release)

Provectus Receives counseling From FDA On tract to Approval for state of matter 3 Trial ... business concern Wire (press release) Its dermatological drug PH-10 too targets abnormal or pathologic cells, with the actual focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase ii trials of PV-10 As a therapy for pathological process melanoma, and of PH-10 as a topical ... and more » Link To Article